ArticleResearch square2026
Acute and long-term effects of repetitive transcranial magnetic stimulation in major depressive episodes: a systematic review and dose-response meta-analysis of randomized sham-controlled trials.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: To characterize the dose-response relationships between key repetitive transcranial magnetic stimulation (rTMS) dosing parameters and clinical outcomes in major depressive episodes (MDE), and to identify optimal dosing ranges. Methods: We performed a systematic review and one-stage dose-response meta-analysis of randomized sham-controlled trials investigating rTMS for adults with MDE. Outcomes were symptom severity, response, and remission, assessed acutely and in follow-up (> 7 days). Four key dosing dimensions (total pulses, pulses/session, sessions, duration) were modeled using restricted cubic spline models, and the maximum effective dose (EDmax) within the observed range was derived from the fitted model. Effect sizes were expressed as standardized mean differences and risk ratios with 95% confidence interval. Results: Across 108 trials (134 active arms; n = 5,621), total pulses, pulses per session, total sessions and treatment duration showed significant non-linear associations with acute efficacy. Peak efficacy for acute treatment was observed at 30,000-39,000 total pulses, 1,800-2,200 pulses per session, 14-16 sessions, and 2.7-3.1 weeks of treatment, with no additional benefit from higher doses across all parameters. Long-term analyses showed smaller and mostly linear associations: the best outcomes were generally observed at 26,000-33,000 total pulses, 1,300-1,800 pulses per session, 10-14 sessions, and 2.8-3.3 weeks of treatment. Sensitivity analyses confirmed the stability of these estimates, and publication bias was minimal. Conclusions: rTMS efficacy in MDE is maximized within a moderate dose range, beyond which additional stimulation yields minimal gain. Thus, sustained remission likely depends on maintenance strategies, not dose escalation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.